Showing 1 - 10 of 17,959
The U.S. Food and Drug Administration (FDA) balances risks and benefits before approving pharmaceuticals, as …
Persistent link: https://www.econbiz.de/10014148944
Persistent link: https://www.econbiz.de/10009379464
The valuation of multi-staged pharmaceutical R&D can be interpreted as a chain of real options. In valuing these compound option models, a crucial problem is how to deal with the different types of risk. Previous models, such as Cassimon et al. (2004), offer a closed-form solution for the...
Persistent link: https://www.econbiz.de/10014162803
Research on the statutory license for certain types of copyright-protected content has revealed an unlikely symbiosis between uncertainty and efficiency. Contrary to received wisdom, which tells us that in order to increase efficiency, we must increase stability, this Article will show that...
Persistent link: https://www.econbiz.de/10014154519
Persistent link: https://www.econbiz.de/10011318463
Persistent link: https://www.econbiz.de/10010251098
Persistent link: https://www.econbiz.de/10010207164
Persistent link: https://www.econbiz.de/10011989174
The classical Uncertainty of Outcome Hypothesis (UOH) informs economists' understanding consumer decisions to attend sporting events and models of team revenue generation. Coates, Humphreys and Zhou (2014) developed a reference dependent preference based consumer choice model under uncertainty...
Persistent link: https://www.econbiz.de/10012976940
Persistent link: https://www.econbiz.de/10009785662